Par Health Recalls Argatroban Injection Lots
The manufacturer issued a recall for 22 lots of the medication due to the presence of foreign particulate matter.
Updated on Oct. 20, 2026 in Stroke
Live Poll
Do frequent pharmaceutical product recalls reduce your personal trust in the safety of your prescribed medication?
Par Health has initiated a nationwide recall of 22 lots of Argatroban Injection after discovering foreign particulate matter in the medication. The substance is used as a heparin substitute to treat and prevent blood clots.
Why it matters
The presence of materials such as stainless steel and plastic in an injectable drug poses severe health risks to patients. Contaminants can lead to life-threatening pulmonary emboli, organ damage, or dangerous inflammation of the veins.
The recall involves 22 lots of Argatroban Injection distributed nationwide between December 30, 2024, and May 5, 2026. As of October 20, 2026, health officials have confirmed that no adverse events have been reported.
The players
Par Health
This pharmaceutical company is the manufacturer responsible for the production and subsequent recall of the affected Argatroban Injection lots.
Major Pharmaceuticals
This company is a separate pharmaceutical firm that previously issued a recall for nearly 300,000 capsules of the anticoagulant medication Pradaxa.
The details
The recalled medication contains various foreign particles, including cellulose, stainless steel, polystyrene, polyethylene terephthalate, and stopper material. Hospital pharmacies and wholesale distributors are required to stop using and distributing the affected lots immediately and notify all relevant accounts.
Timeline
Dec. 30, 2024: Distribution of the recalled Argatroban lots began.
May 5, 2026: Distribution of the recalled Argatroban lots concluded.
August 2026: Major Pharmaceuticals conducted a separate recall of 299,520 Pradaxa capsules.
Oct. 20, 2026: Officials confirmed that no adverse patient events had been reported.
Health Landscape
This action follows the pattern set by the August 2026 Major Pharmaceuticals recall of Pradaxa capsules. It underscores a recent period of increased quality control scrutiny for injectable and blood-thinning medications across the industry.
Patients who have recently received or are currently using Argatroban should consult their healthcare providers regarding the safety of their medication. Hospitals and pharmacies must verify their current inventory against the recalled lot numbers to ensure clinical safety.
The takeaway
Patients and medical providers should prioritize verifying medication lot numbers during this recall period to avoid exposure to physical contaminants. Always ensure that healthcare facilities are following updated safety notifications from pharmaceutical manufacturers.
Further reading
For more information on the management of clotting disorders and associated treatments, visit the Stroke section.
Live Poll
Do frequent pharmaceutical product recalls reduce your personal trust in the safety of your prescribed medication?
